Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	31431-39-7
Formula :	C₁₆H₁₃N₃O₃
M.W :	295.29
SMILES Code :	COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C1=CC=CC=C1
Synonyms :	NSC 184849; Vermox; Wormkuur
MDL No. :	MFCD00057872
InChI Key :	OPXLLQIJSORQAM-UHFFFAOYSA-N
Pubchem ID :	4030

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H351-H361
Precautionary Statements:	P280-P305+P351+P338

GMR-AML1 cells	>300 nM	72 hours	MB treatment induced loss of viability in GMR-AML1 cells	PMC10844204
HL1 cardiomyocytes	6.25 μM		Mebendazole increased cardiomyocyte viability	PMC4360984
FPD-MM cells	1000 nM	24 hours	MB treatment reduced chromatin accessibility and protein expression	PMC10844204
MDA-MB-468	0.5 μM	24 hours	Evaluate cytotoxicity of 806-PE38 on MDA-MB-468 cells, IC50 was 7 ng/mL	PMC7381743
UW228 medulloblastoma cells	1 μM	24 hours	To evaluate the effect of MBZ on tubulin polymerization in UW228 cells. Results showed 1 μM MBZ significantly reduced tubulin polymerization in UW228 cells.	PMC4483072
D425 medulloblastoma cells	1 μM	24 hours	To evaluate the effect of MBZ on tubulin polymerization in D425 cells. Results showed 1 μM MBZ had no significant effect on tubulin polymerization in D425 cells.	PMC4483072
Human umbilical vein endothelial cells (HUVECs)	1-10 μM	30 minutes	To evaluate the effect of R-2-HG on endothelial cell migration, results showed that R-2-HG significantly enhanced the migration ability of HUVECs.	PMC4483072
060919 human GBM neurosphere cells	0.1 μM	72 hours	Evaluate the cytotoxicity of mebendazole on 060919 cells, showing an IC50 of approximately 0.1 μM.	PMC3158014
GL261 mouse glioma cells	0.24 μM	72 hours	Evaluate the cytotoxicity of mebendazole on GL261 cells, showing an IC50 of 0.24 μM.	PMC3158014
MDA-MB-231	0.5 μM	24 hours	Evaluate the toxicity of HTCG@TA on MDA-MB-231 cells, results showed only 32% cell survival	PMC7381743

Nude mice	PTCH1-mutant medulloblastoma allograft model and D425 medulloblastoma xenograft model	50 mg/kg	Oral gavage	Once daily, continuous treatment	To evaluate the effect of MBZ on survival and tumor angiogenesis in medulloblastoma models. Results showed MBZ significantly extended survival in PTCH1-mutant and D425 medulloblastoma models and inhibited tumor angiogenesis.	PMC4483072
C57BL/6 mice	GL261 syngeneic glioma model	50 mg/kg	Oral gavage	Daily for the first 20 days, then 5 days per week	Evaluate the therapeutic effect of mebendazole on the GL261 glioma model, showing mean survival extended from 30 days to 49 days, a 63.3% increase.	PMC3158014
Mouse	Heligmosomoides polygyrus infection model	200 L3 larvae/mouse	Oral gavage	Single infection, lasting 14 days	To study the effect of Mebendazole on anti-parasitic immune responses in Heligmosomoides polygyrus-infected mice. Results showed that Mebendazole was not used in the experiments.	PMC9109499
Nude mice	Xenograft tumor model	10, 20, 40 mg/Kg/day	Subcutaneous injection	Once daily until the end of the experiment	To evaluate the anti-tumor effect of Flubendazole in vivo, results showed that Flubendazole significantly inhibited tumor growth	PMC7381743
Zebrafish	Doxorubicin-induced cardiomyopathy model	1 μM		48 hours	Mebendazole protected zebrafish from doxorubicin-induced cardiotoxicity and death	PMC4360984
NSG mice	GMR-AML1-Luc/GFP xenograft model	20 mg/kg and 40 mg/kg		3 weeks and 4 weeks	MB monotherapy significantly reduced leukemia burden and improved survival	PMC10844204

{[proInfo.proName]}

CAS No.: 31431-39-7

{[proInfo.proName]}

CAS No.: 31431-39-7

Alternative Products

Product Details of Mebendazole

Safety of Mebendazole

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00000314	Cocaine-Related Disorders	Phase 2	Completed	-	United States, New York ... More >> VA Medical Center Brooklyn, New York, United States, 11209 Less <<
NCT00080444	Vomiting	Phase 3	Completed	-	-
NCT03472573	Recurrent B Acute Lymphoblasti... More >>c Leukemia Refractory B Acute Lymphoblastic Leukemia Less <<	Phase 1	Recruiting	November 2020	United States, Pennsylvania ... More >> Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Margaret Kasner, MD 215-955-8874 margaret.kasner@jefferson.edu Principal Investigator: Margaret Kasner, MD Less <<
NCT01161069	Healthy	Phase 1	Completed	-	Belgium ... More >> Pfizer Investigational Site Bruxelles, Belgium, 1070 Less <<
NCT01208233	Ischemic Stroke	Phase 2	Terminated(See termination rea... More >>son in detailed description.) Less <<	-	-
NCT01208233	-		Terminated(See termination rea... More >>son in detailed description.) Less <<	-	-
NCT02492334	PTSD Alcohol ... More >>Use Disorder Less <<	Phase 1 Phase 2	Recruiting	March 2019	United States, South Carolina ... More >> Addiction Sciences Division-Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29425 Contact: Megan M Moran-Santa Maria, Ph.D. moranm@musc.edu Contact: Francis M Beylotte, MS 8437922522 ext Beylotte beylott@musc.edu Sub-Investigator: Julianne Flanagan, Ph.D. Principal Investigator: Sudie Back, Ph.D. Less <<
NCT03558464	Stunting Anem... More >>ia Micronutrient Deficiency Less <<	Not Applicable	Recruiting	April 30, 2021	Kenya ... More >> One Acre Fund Recruiting Kakamega, Kenya Contact: Kelvin Musau, MSc +254711534867 kelvin.musau@oneacrefund.org Principal Investigator: Kelvin Musau, MSc Sub-Investigator: Haley Kawaja, MSc Sub-Investigator: Marion Kiprotich, MSc Less <<
NCT02366884	Neoplasms	Phase 2	Enrolling by invitation	December 31, 2020	United States, Maryland ... More >> Atavistic Chemotherapy Clinical Trial Bethesda, Maryland, United States, 20814 Mexico Dr. Frank Arguello Cancer Clinic San Jose del Cabo, Baja California Sur, Mexico Instituto de Ciencia y Medicina Genomica Torreon, Coahuila, Mexico Less <<
NCT01450683	Prostate Cancer ... More >> Prostatic Neoplasms Castrate-resistant Prostate Cancer (CRPC) Androgen-insensitive Prostate Cancer Hormone-refractory Prostate Cancer Metastatic Disease Less <<	Phase 2	Terminated(Low accrual)	-	United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Less <<
NCT01450683	-		Terminated(Low accrual)	-	-
NCT01080989	Flavivirus Infection ... More >> Alphavirus Infections Malaria Parasitic Disease Leptospirosis Hypertension Metabolic Syndromes Less <<	Not Applicable	Completed	-	Taiwan ... More >> Kaoshing Medical University Chung-Ho Memorial Hospital Kaoshiung, Taiwan Less <<
NCT01395381	Kwashiorkor M... More >>arasmus Less <<	Not Applicable	Withdrawn(not funded)	-	Malawi ... More >> St. Louis Nutrition Project Blantyre, Malawi Less <<
NCT02876146	Alveolar Echinococcosis	Not Applicable	Active, not recruiting	June 2023	-
NCT02152527	-		Completed	-	Croatia ... More >> School of Medicine, University of Split Split, Croatia, 21000 Less <<
NCT01905423	-		Completed	-	-
NCT01905423	-		Completed	-	Indonesia ... More >> University of Indonesia, Department of Parasitology Jakarta, Java, Indonesia, 10430 Less <<
NCT02255461	Childhood Choroid Plexus Tumor... More >> Childhood Ependymoblastoma Childhood Grade III Meningioma Childhood High-grade Cerebellar Astrocytoma Childhood High-grade Cerebral Astrocytoma Childhood Medulloepithelioma Recurrent Childhood Anaplastic Astrocytoma Recurrent Childhood Anaplastic Oligoastrocytoma Recurrent Childhood Anaplastic Oligodendroglioma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Giant Cell Glioblastoma Recurrent Childhood Glioblastoma Recurrent Childhood Gliomatosis Cerebri Recurrent Childhood Gliosarcoma Recurrent Childhood Medulloblastoma Recurrent Childhood Pineoblastoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Less <<	Phase 1	Recruiting	December 31, 2018	United States, California ... More >> Childrens Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Girish Dhall 323-361-4629 gdhall@chla.usc.edu Principal Investigator: Girish Dhall Lucile Packard Children Hospital Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Paul G. Fisher 650-721-5889 pfisher@stanford.edu Principal Investigator: Paul G. Fisher United States, District of Columbia Childrens National Medical Center Recruiting Washington, District of Columbia, United States, 20010-2970 Contact: Eugene Hwang, MD 202-476-5046 ehwang@childrensnational.org Principal Investigator: Lindsay B Kilburn, MD Sub-Investigator: Roger Packer, MD Sub-Investigator: Brain Rood, MD Sub-Investigator: Eugene Hwang, MD United States, Illinois Lurie Childrens Hospital-Chicago Recruiting Chicago, Illinois, United States, 60614 Contact: Stewart Goldman 312-227-4874 sgoldman@luriechildrens.org Principal Investigator: Stewart Goldman, MD Sub-Investigator: Jason Fangusaro, MD Sub-Investigator: Rishi Lulla, MD Sub-Investigator: Natasha Pillay-Smiley, MD United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Ira Dunkel 212-639-2153 dunkeli@mskcc.org Principal Investigator: Ira Dunkel United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: David Van Mater, MD, PhD 919-684-3401 david.vanmater@duke.edu Principal Investigator: David Van Mater United States, Ohio Cincinnati Children Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Maryam Fouladi 513-803-0721 maryam.fouladi@cchmc.org Principal Investigator: Maryam Fouladi United States, Pennsylvania Children Hospital of Pittsburgh of UPMC Recruiting Pittsburgh, Pennsylvania, United States, 15224 Contact: Ian Pollack 412-692-5881 Pollaci@chp.edu Sub-Investigator: Ian Pollack, MD Principal Investigator: A. Kim Ritchey, MD United States, Tennessee St. Jude Children Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Giles Robinson, MD 901-595-2907 giles.robinson@stjude.org Principal Investigator: Zsila Sadighi, MD Sub-Investigator: Amar Gajjar, MD United States, Texas Texas Childrens Hospital Recruiting Houston, Texas, United States, 77030 Contact: Patricia M. Baxter, MD 832-824-4681 pabaxter@txch.org Sub-Investigator: Murali M. Chintagumpala Principal Investigator: Patricia Baxter United States, Washington Seattle Children Hospital Recruiting Seattle, Washington, United States, 98105 Contact: Sarah Leary 206-987-2106 sarah.leary@seattlechildrens.org Principal Investigator: Sarah Leary Less <<
NCT03014167	Helminthiasis ... More >> Filariasis Less <<	Phase 4	Recruiting	December 2022	Benin ... More >> Institut de Recherche pour le Développement Recruiting Comé, Benin Contact: Adrian Luty, PhD, DR adrian.luty@ird.fr India Christian Medical College Recruiting Vellore, India Contact: Gagandeep Kang, MBBS, MD, PhD gkang@cmcvellore.ac.in Malawi London School of Hygiene and Tropical Medicine Recruiting Mangochi, Malawi Contact: Robin Bailey, MA, BM, MRCP, DTM&H, PhD, FRCP robin.bailey@lshtm.ac.uk Less <<
NCT03539731	Healthy Subject ... More >> Intracranial Neoplasm Recurrent Glioblastoma Less <<	Phase 1	Recruiting	April 23, 2020	United States, California ... More >> Stanford University, School of Medicine Recruiting Palo Alto, California, United States, 94304 Contact: Hari Priya M. Yerraballa 650-724-9363 yhpriya@stanford.edu Principal Investigator: Sanjiv Gambhir Less <<
NCT00116493	Anemia	Phase 3	Completed	-	Pakistan ... More >> Aga Khan University Karachi, Sindh, Pakistan Less <<
NCT00148629	Anemia Low Bi... More >>rth Weight Neonatal Mortality Less <<	Phase 3	Unknown	-	Tanzania ... More >> Public Health Laboratory "Ivo de Carneri" Wawi, Zanzibar, Tanzania Less <<
NCT02420574	Helminthiasis	Not Applicable	Completed	-	-
NCT02201381	Cancer Overal... More >>l Survival Less <<	Phase 3	Recruiting	October 22, 2023	United Kingdom ... More >> Care Oncology Clinic Recruiting London, United Kingdom, W1G 9PP Contact: Gregory Stoloff +44 207 580 3266 info@careoncologyclinic.com Contact: Robin Bannister, PhD +44 207 153 6577 robin.bannister@seekacure.com Less <<
NCT01898871	Wasting Moder... More >>ate Acute Malnutrition Less <<	Phase 2	Completed	-	Cameroon ... More >> Evodoula Health District Evodoula, Cameroon Biyem Assi District Centre Yaounde, Cameroon Less <<
NCT01050452	Parasitic Diseases	Not Applicable	Completed	-	Uganda ... More >> Vector Control Division Kampala, Uganda Less <<
NCT01314937	Malnutrition ... More >>Intestinal Diseases, Parasitic Less <<	Phase 4	Completed	-	Peru ... More >> Asociacion Civil Selva Amazonica Iquitos, Loreto, Peru Less <<
NCT03278431	Hookworm Infection	Phase 4	Completed	-	Lao People's Democratic Republ... More >>ic Nambak District Hospital Luang Prabang, Lao People's Democratic Republic, 0604 Less <<
NCT01327469	Infection by Trichuris Trichiu... More >>ra Less <<	Phase 4	Completed	-	Ethiopia ... More >> Jimma University Jimma, Ethiopia Less <<
NCT03757403	Idiopathic Pruritus Ani	Phase 2	Not yet recruiting	January 31, 2020	United Kingdom ... More >> The Atherstone Surgery Not yet recruiting Atherstone, United Kingdom, CV9 1EU Contact: Jeanette Melrose, MD University Hospitals Bristol NHS Foundation Trust- Location Bristol Royal Infirmary Not yet recruiting Bristol, United Kingdom, IG95LP Contact: Debbie Shipley, MD Kings Medical Centre Buckhurst Hill, United Kingdom, IG95LP Sheepcot Medical Centre Not yet recruiting Watford, United Kingdom, WD25 7NL Contact: Alan Jackson, MD Less <<
NCT01050374	Parasitic Diseases	Not Applicable	Completed	-	Uganda ... More >> Vector Control Division Kampala, Uganda Less <<
NCT01379326	Ascaris Lumbricoides\|Ascaris S... More >>uum\|Trichuris Trichiura\|Trichuris Vulpis\|Ancylostoma Duodenal\|Ancylostoma Caninum\|Ancylostoma Ceylanicum\|Necator Americanus Less <<	PHASE4	COMPLETED	2025-12-12	Fundacion Huesped, Buenos Aire... More >>s, Argentina\|Commonwealth Scientific and Industrial Research Organisation, Brisbane, Australia\|Queensland Institute for Medical Research, University of Queensland, Herston QLD, Australia\|Funda??o Oswaldo Cruz, Belo Horizonte, Brazil\|Institut Pasteur in Cambodia, Clinical Pathology Unit, Phnom Penh, Cambodia\|University of Yaoundé I, Yaoundé I, Cameroon\|College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia\|Ivo de Carneri, Pemba Island, Zanzibar, Tanzania\|National Institute for Malariology, Parasitology and Entomology, Hanoi, Vietnam Less <<
NCT01837862	Pilomyxoid Astrocytoma ... More >> Pilocytic Astrocytoma Glioma, Astrocytic Optic Nerve Glioma Pleomorphic Xanthoastrocytoma Glioblastoma Multiforme Anaplastic Astrocytoma Gliosarcoma Diffuse Intrinsic Pontine Glioma DIPG Low-grade Glioma Brainstem Glioma Less <<	Phase 1 Phase 2	Recruiting	April 2020	United States, New York ... More >> Cohen Children's Medical Center of New York Recruiting New Hyde Park, New York, United States, 11040 Contact: Mark P Atlas, MD 718-470-3460 matlas@nshs.edu Contact: Derek R Hanson, MD 551-996-5437 DHanson@hackensackumc.org Principal Investigator: Mark P Atlas, MD Sub-Investigator: Derek R Hanson, MD Sub-Investigator: Arlene Redner, MD Sub-Investigator: Mohamad Badawi, MD Sub-Investigator: Avery Wright, DO Less <<
NCT01350271	Necator Americanus Infection	Phase 3	Completed	-	Sri Lanka ... More >> Agalawatta Plantations PLC Nivitigala, Sabragamuwa, Sri Lanka Lellopitiya Estate, Hapugastenne Plantations PLC Ratnapura, Sabragamuwa, Sri Lanka Less <<
NCT01350271	-		Completed	-	-
NCT02385058	Helminthiasis ... More >> Amoebiasis Less <<	Phase 4	Completed	-	Mexico ... More >> Mex, Mexico Less <<
NCT01173562	Healthy Volunteers	PHASE3	COMPLETED	2025-03-10	Pemba, Tanzania
NCT02034162	-		Completed	-	-
NCT02034162	Helminth Infections	Phase 3	Completed	-	Ethiopia ... More >> Gondar, Ethiopia Jimma, Ethiopia Rwanda Kigali, Rwanda Less <<
NCT02051738	Healthy	Phase 1	Completed	-	Belgium ... More >> Merksem, Belgium Less <<
NCT03628079	Cancer of the Gastrointestinal... More >> Tract Cancer of Unknown Origin Less <<	Phase 1 Phase 2	Recruiting	June 2020	Sweden ... More >> Dept of oncology, University Hospital Recruiting Uppsala, Sweden, 75185 Less <<
NCT03245398	Hookworm	Phase 4	Completed	-	Tanzania ... More >> Public Health Laboratory Ivo de Carneri, P.O. Box 122 Chake Chake, Pemba, Tanzania Less <<
NCT03261596	Hookworm Infections	PHASE4	WITHDRAWN	2025-12-17	Noguchi Memorial Institute for... More >> Medical Research - University of Ghana, Legon, Accra, Ghana Less <<
NCT01729260	Newly Diagnosed High-Grade Gli... More >>oma Less <<	PHASE1	COMPLETED	2021-04-16	The Johs Hopkins Hospital, Bal... More >>timore, Maryland, 21287, United States Less <<
NCT02644291	Medulloblastoma\|Astrocytoma, G... More >>rade III\|Glioblastoma\|Anaplastic Astrocytoma\|Brain Stem Neoplasms, Malignant\|Oligodendroblastoma\|Anaplastic Oligodendroglioma\|Malignant Glioma Less <<	PHASE1	COMPLETED	2022-06-09	Johns Hopkins All Children's H... More >>ospital, Saint Petersburg, Florida, 33701, United States\|Johns Hopkins University School of Medicine, Baltimore, Maryland, 21231, United States Less <<
NCT03995680	Hookworm Infections	PHASE2	COMPLETED	2019-10-09	Public Health Laboratory Ivo d... More >>e Carneri, Chake Chake, Tanzania Less <<
NCT06335160	Ulcerative Colitis		NOT_YET_RECRUITING	2025-05-25	-

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed